BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11342309)

  • 1. Infusional vinorelbine in relapsed or refractory lymphomas.
    Sarris AH; Psyrri A; Hagemeister F; Romaguera J; McLaughlin P; Rodriguez MA; Bachier C; Younes A; Mesina O; Oholendt M; Medeiros LJ; Samuels B; Adams LM; Cabanillas F
    Leuk Lymphoma; 2000 Oct; 39(3-4):291-9. PubMed ID: 11342309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
    Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
    Ibrahim NK; Rahman Z; Valero V; Willey J; Theriault RL; Buzdar AU; Murray JL; Bast R; Hortobagyi GN
    Cancer; 1999 Oct; 86(7):1251-7. PubMed ID: 10506711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.
    Ibrahim NK; Valero V; Rahman Z; Theriault RL; Walters RS; Buzdar AU; Booser DJ; Holmes FA; Murray JL; Willey J; Bast R; Hortobagyi GN
    Cancer Invest; 2001; 19(5):459-66. PubMed ID: 11458813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous-infusion vinorelbine for the treatment of advanced non-small-cell lung cancer: a phase I/II study.
    Carabante-Ocón F; Cobo-Dols M; Benavides-Orgaz M; Gil-Calle S; Alés-Díaz I; Bretón-García JJ; Villar-Chamorro E; Montesa-Pino A; Alcalde-García J; Gutiérrez-Calderón V
    Clin Lung Cancer; 2005 Sep; 7(2):121-6. PubMed ID: 16179099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
    Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
    Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
    Leuk Lymphoma; 2006 Oct; 47(10):2155-62. PubMed ID: 17071490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F
    Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.
    Sarris AH; Hagemeister F; Romaguera J; Rodriguez MA; McLaughlin P; Tsimberidou AM; Medeiros LJ; Samuels B; Pate O; Oholendt M; Kantarjian H; Burge C; Cabanillas F
    Ann Oncol; 2000 Jan; 11(1):69-72. PubMed ID: 10690390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
    Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
    Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.
    Sarris AH; Phan A; Goy A; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Medeiros LJ; Samuels B; Mesina O; Bleyer AW; Cabanillas F
    Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):27-31. PubMed ID: 12199630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
    Press OW; LeBlanc M; O'Rourke TJ; Gagnet S; Chapman RA; Balcerzak SP; Fisher RI
    J Clin Oncol; 1998 Feb; 16(2):574-8. PubMed ID: 9469343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas.
    Goss P; Stewart AK; Couture F; Klasa R; Glück S; Kaizer L; Burkes R; Charpentier D; Palmer M; Tye L; Dulude H
    Leuk Lymphoma; 1999 Jul; 34(3-4):295-304. PubMed ID: 10439366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
    Foss FM; Parker T
    Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.